Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ovaflow
- Development stage
- Phase 4
- Lead developer
- Supercare Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ovaflow is a dietary supplement marketed by Supercare Pharma, primarily indicated for the management of Polycystic Ovary Syndrome (PCOS) and the improvement of female fertility. The formulation typically combines Myo-inositol, D-chiro-inositol, and Folic acid. These ingredients function as insulin-sensitizing agents that help regulate hormonal imbalances, improve ovulatory function, and enhance oocyte quality in women struggling with metabolic and reproductive issues associated with PCOS. While Supercare Pharma is an e-commerce retail pharmacy, it distributes this product under its own brand in the Nigerian market.
- Brand names
- Ovaflow
02
Targets
FOLR1 (FRα)INSR (Insulin receptor)
Beyond the preview
Go deeper on Ovaflow.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ovaflow.